<DOC>
	<DOCNO>NCT00902018</DOCNO>
	<brief_summary>The purpose study evaluate effect eltrombopag platelet subject chronic ITP . Eltrombopag approve Food Drug Administration ( FDA ) treatment low platelet patient chronic ITP . It study GlaxoSmithKline condition associate low platelet . This research study do eltrombopag show increase platelet count different way therapy ITP . The investigator want study eltrombopag affect subject platelet determine study drug best use ITP treatment .</brief_summary>
	<brief_title>Eltrombopag Bcl-extra-large ( xL ) Pathway Idiopathic Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description>The B-cell lymphoma extra large ( Bcl-xL/Bak ) balance identify intrinsic mechanism critical determine platelet lifespan ( Mason , Cell 2007 ) . There evidence Bcl-xL protein expression megakaryocyte regulate Thrombopoietin ( TPO ) mediate activation Akt pathways mediate Jak2 Stat 5 ( possibly Stat 3 well ) . ( e.g. , Kozuma et . al. , Journal Thrombosis Haemostasis ) . Little known Bcl-xL / Bak axis patient ITP , effect TPO-R stimulation platelet survival patient ITP . The TPO effect may result stimulation thrombopoietin-receptor ( TPO-R ) signal megakaryocyte alter package Bcl-xl platelet , direct effect platelet TPO-R stimulation describe .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Subject sign dated write informed consent Male female adult ( ≥18 year ) diagnose either primary ITP accord American Society Hematology British Committee Standards Haematology ( ASH/BCSH ) guideline [ Blood , 1996 ; British Journal Haematology , 2003 ] least three month prior study entry ITP secondary Evans syndrome , systemic lupus erythematosus ( SLE ) , Common Variable Immunodeficiency ( include hypogammaglobulinemia ) . Subjects must respond platelet count &gt; 30,000/µL previous ITP therapy include thrombopoietic agent . Platelet count &lt; 30,000/µL Female subject childbearing potential practicing acceptable method contraception completely abstinent intercourse . Active infection Previously treat thrombopoietic agent IF either response therapeutic dose ( peak platelet count &lt; 50k ) OR treatment agent within past 4 week Currently treat concomitant ITP medication stable dose least 2 week prednisone , azathioprin , danazol allow . Female subject nurse pregnant Thrombosis kind within past 6 month blood thinner thrombosis . Intravenous Immunoglobulin ( IVIG ) , IV antiD , bolus corticosteroid vinca alkaloid within past week Other cytotoxic immunosuppressive ITP therapy within past 8 week rituximab within past 12 week Active nondermatologic malignancy define presence know tumor ie . visible radiography evident blood bone marrow test OR receive chemotherapy within past 2 month Hemoglobin &lt; 10 gm/dl white blood cell count &lt; 2,500/ul Liver function test ( ALT , Aspartate Aminotransferase ( AST ) , total bilirubin ) &gt; three time upper limit normal ( ULN ) Creatinine &gt; two time upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ITP</keyword>
</DOC>